贝罗司他胶囊使用说明|贝罗司他副作用介绍

Orladeyo, a plasma kallikrein inhibitor, is a new, oral, once-daily, potent, selective human plasma kallikrein inhibitor that prevents edema attacks by inhibiting kallikrein to prevent the production of bradykinin. Today let’s learn about the instructions for use of Berostat Capsules | Introduction to the side effects of Berostat.

The use of Berostat capsules is relatively simple. The recommended dosage of Berostat is:

Take one capsule (150 mg) orally once daily with food. Patients should not increase or decrease the dosage of the drug without authorization during treatment with Orladeyo. Increasing the dosage of the drug will not make the condition improve quickly, but will lead to adverse reactions. Therefore, patients should strictly follow the doctor's diagnosis and treatment recommendations and should not use medication without authorization.

As follows:

1. Heart rhythm problems. Taking more than one Orladeyo capsule a day may cause QT prolongation, a condition that causes an abnormal heartbeat.

2. The most common adverse reactions (≥10%) of beroxstat are abdominal pain, vomiting, diarrhea, back pain and gastroesophageal reflux disease.

3. Less common side effects of Berostat include: abnormal liver function indicators.

4. A rare side effect of Berostat: transient, itchy rash.

Patients should not increase or decrease the dose of the drug without authorization during treatment with Berostat Oradejo. Increasing the dose of the drug will not make the condition improve quickly, but will lead to adverse reactions. Therefore, patients should strictly follow the doctor's diagnosis and treatment recommendations and should not use drugs without authorization. When side effects occur, contact your attending physician promptly to seek solutions.

Currently, Orladeyo, berosostat capsules, has been approved by the U.S. Food and Drug Administration (FDA) for the prevention of hereditary angioedema (HAE) attacks in children and adult patients aged ≥12 years. Berosostat capsules are the first targeted oral therapy approved to prevent HAE attacks. The approval of berosostat will bring significant progress in the treatment of HAE patients with hereditary angioedema and will help reduce the treatment burden on patients.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.